DRUGS recently approved around the world to fight cancer increased patients' overall survival, but benefits vary depending on the drug, a new study shows.
Researchers looked at the 62 cancer drugs approved in the U.S. and Europe between 2003 and 2013 and found they extended survival by an average of about 3.5 months.
But nearly a third of the drugs lacked evidence to suggest they increased survival when compared to alternative treatments.
"Our results point to the notion that new cancer treatments may not always provide patients with greater clinical benefits, or lower risks, over existing treatments," wrote senior researcher Dr. Elias Mossialos, of the London School of Economics and Political Science, in an email to Reuters Health.
The risk-benefit ratio of new drugs is especially important if people are concerned, for example, about whether the cost of a drug would make it difficult for a person to complete the treatment regimen.
Writing in JAMA Oncology, Mossialos and colleagues point to growing questions about the value of new cancer medicines. While the drugs' high costs may be a barrier to access, they note, some people argue the high prices are justified if the treatments offer large benefits.
A lack of solid data on new drugs' benefits and risks makes it difficult to evaluating their value.
For the 62 medicines they wanted to study, the researchers found data from England, France and Australia evaluating 53 drugs. Nearly 80 percent were tied to improvements in survival, quality of life or safety.
The drugs increased survival - with or without recurrence - by about 3.5 months on average, compared to other treatments available in 2003.
Twenty-three drugs were individually tied to an increase in survival of three months or more. Six drugs extended survival by less than three months. Eight drugs increased survival by an unknown amount. And for 16 of the approved drugs, there was no evidence to suggest they were better than alternative treatments at extending survival.
The researchers point out in an email that overall survival benefits differed by the type of drug. For example, drugs for thyroid cancer were tied to no increase in overall survival, while drugs to treat breast cancer were linked to an average increase of about 8.5 months.
Twenty-two of the drugs were tied to an improved quality of life, but 24 were linked to worse patient safety, which include side effects and whether a person could tolerate the treatment.
The researchers write in their email that they extending the study to look at newer drugs. They are also working to link their evidence with the cost of individual medicines.
Mossialos said the study should remind people of the importance of the relationship between doctors and patients. He said, "Patients should work with their physicians to consider all available evidence that exists in support of individual treatments, and use this alongside any inputs from their clinician to identify the treatment that would best correspond with their own medical and personal circumstances."
Reuters
Tue Jan 03 2017
The drugs increased survival - with or without recurrence - by about 3.5 months on average, compared to other treatments available in 2003. - Photo for illustration purpose only
Tiga anggota polis direman kes rasuah pemandu lori
Tiga anggota polis direman empat hari sehingga Ahad bagi membantu siasatan kerana disyaki meminta dan menerima rasuah daripada pemandu lori di Mersing.
DOSM tambah 300 kaunter daftar PADU
Jabatan Perangkaan menambah 300 kaunter fizikal di seluruh negara dalam memastikan proses mengemas kini maklumat dalam sistem PADU lancar.
Wanita 20 tahun ke atas disaran jalani saringan kesihatan kesan NCD
"Jangan tunggu ada simptom baru nak uji, masa tu tak tahu sama ada komplikasi sudah berlaku atau tidak."
India bantah keras kenyataan AS berhubung penahanan Ketua Menteri Delhi
Pandangan negara luar berhubung penahanan Kejriwal dilihat telah merisaukan Kerajaan India.
Kuasa bekukan permit pemindahan padi antara negeri di bawah Akta 522 - KPB
Kuasa membekukan permit pemindahan padi antara negeri adalah di bawah Akta Kawalan Padi dan Beras 1994 (Akta 522) melalui fungsi Ketua Pengarah KPB.
Air Balang RM1 jadi tumpuan Bazar Ramadan Temenggong, Kulai
Bukan sekadar berniaga, pengusaha Air Balang RM1 juga ambil kesempatan lakukan jariah di bulan penuh kemuliaan.
Anggota polis didakwa minta, terima rasuah direman empat hari
Tiga anggota polis direman selama empat hari bagi membantu siasatan berhubung dakwaan meminta dan menerima rasuah berjumlah RM7,800.
Persembahan bertenaga Dolla pukau penonton di China
Aksi bertenaga mereka mendapat sambutan hangat daripada penonton di negara itu, menandakan langkah berani Dolla keluar dari zon selesa di negara ini mula menampakkan hasil.
AWANI Ringkas: Agihan RM0.67 bilion
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
Bedah siasat: PSM libatkan jururunding, kontraktor padang SNBJ
Perbadanan Stadium Malaysia akan mengadakan mesyuarat 'post mortem' bersama juruperunding dan kontraktor padang Stadium Nasional Bukit Jalil (SNBJ) minggu hadapan.
Memerangi kanser payudara ketika pandemik COVID-19
Kebanyakan kanser payudara bermula dari sel yang melapisi bahagian saluran (ductal cancer), sebahagian lain bermula pada kelenjar lobul (lobular cancer) dan selebihnya bermula dari tisu-tisu lain.
Pesakit kanser cabar diri sendiri terima kad Krismas dari seluruh Amerika
Ternyata dengan kuasa media sosial, Ryan menerima 3000 kad daripada kesemua 50 negeri di Amerika Syarikat dan 29 negara.
Angelina Jolie umum buang ovari bimbang terjadi kanser
Angelina Jolie hari ini mengumumkan bahawa beliau telah menjalani pembedahan membuang ovari dan tiub fallopio dua tahun lepas.